Genfit Past Earnings Performance
Past criteria checks 0/6
Genfit has been growing earnings at an average annual rate of 35%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 19.7% per year.
Key information
35.0%
Earnings growth rate
42.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 19.7% |
| Return on equity | -42.5% |
| Net Margin | -83.8% |
| Next Earnings Update | 19 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Genfit makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -29 | 19 | 47 |
| 30 Sep 23 | 32 | -32 | 18 | 45 |
| 30 Jun 23 | 29 | -34 | 18 | 44 |
| 31 Mar 23 | 28 | -29 | 18 | 40 |
| 31 Dec 22 | 26 | -24 | 17 | 36 |
| 30 Sep 22 | 60 | 12 | 18 | 33 |
| 30 Jun 22 | 94 | 48 | 18 | 30 |
| 31 Mar 22 | 90 | 58 | 18 | 32 |
| 31 Dec 21 | 85 | 67 | 18 | 35 |
| 30 Sep 21 | 46 | 14 | 17 | 40 |
| 30 Jun 21 | 6 | -39 | 16 | 45 |
| 31 Mar 21 | 7 | -70 | 21 | 52 |
| 31 Dec 20 | 9 | -101 | 25 | 59 |
| 30 Sep 20 | 24 | -84 | 31 | 62 |
| 30 Jun 20 | 39 | -67 | 36 | 64 |
| 31 Mar 20 | 39 | -66 | 34 | 65 |
| 31 Dec 19 | 39 | -65 | 31 | 66 |
| 30 Sep 19 | 23 | -80 | 24 | 70 |
| 30 Jun 19 | 8 | -94 | 18 | 74 |
| 31 Mar 19 | 8 | -87 | 14 | 70 |
| 31 Dec 18 | 7 | -80 | 10 | 67 |
| 30 Sep 18 | 7 | -75 | 10 | 65 |
| 30 Jun 18 | 7 | -70 | 11 | 63 |
| 31 Mar 18 | 7 | -63 | 10 | 58 |
| 31 Dec 17 | 7 | -56 | 9 | 54 |
| 30 Sep 17 | 7 | -50 | 8 | 49 |
| 30 Jun 17 | 8 | -44 | 7 | 44 |
| 31 Mar 17 | 7 | -39 | 8 | 39 |
| 31 Dec 16 | 7 | -34 | 8 | 33 |
| 30 Sep 16 | 6 | -27 | 8 | 26 |
| 30 Jun 16 | 5 | -21 | 7 | 20 |
| 31 Mar 16 | 5 | -19 | 6 | 18 |
| 31 Dec 15 | 4 | -17 | 6 | 16 |
| 30 Sep 15 | 5 | -17 | 4 | 19 |
| 30 Jun 15 | 5 | -17 | 3 | 23 |
| 31 Mar 15 | 6 | -17 | 5 | 20 |
| 31 Dec 14 | 7 | -17 | 6 | 18 |
| 30 Sep 14 | 7 | -15 | 7 | 11 |
| 30 Jun 14 | 7 | -14 | 8 | 5 |
| 31 Mar 14 | 6 | -13 | 8 | 2 |
| 31 Dec 13 | 6 | -13 | 7 | 0 |
| 30 Sep 13 | 6 | -11 | 7 | 0 |
| 30 Jun 13 | 6 | -9 | 7 | 0 |
Quality Earnings: XUP is currently unprofitable.
Growing Profit Margin: XUP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XUP is unprofitable, but has reduced losses over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare XUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XUP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: XUP has a negative Return on Equity (-42.52%), as it is currently unprofitable.